The lipoxins (LXA4, LXB4) are bioactive eicosanoids, derived via the combined action of lipoxygenases on arachidonic acid. While they play a key role in cell-cell interactions and the regulation of inflammatory signals, the bioactions of lipoxins are limited by their rapid enzymatic deactivation.

We have recently engaged in a collaborative effort aimed at the design, synthesis and biological investigation of a series of biostable lipoxin analogues. A number of these molecules were synthesized and shown to exhibit potent bioactivities, particularly against inflammation. Our work has also led to the identification and study of two new lipoxins, 15-epi-LXA4 and 15-epi-LXB4, which are triggered by aspirin and may be associated with some of the beneficial effects of aspirin. The design and synthesis of several new analogs and the development of new synthetic methodology in this area is also being pursued.